Vitamin D deficiency is related to thyroid antibodies in autoimmune thyroiditis by Unal, Asli Dogruk et al.
Central European Journal of Immunology 2014; 39(4) 493
Clinical immunology DOI: 10.5114/ceji.2014.47735
Correspondence: Asll Dogruk Unal, Department of Endocrinology and Metabolism, Baskent University Istanbul Hospital, Mahir Iz str.  
No: 43, Istanbul, Turkey, tel. 90 216 474 23 04, fax 90 216 474 43 44, e-mail: aslidogruk@yahoo.com
Vitamin D deficiency is related to thyroid 
antibodies in autoimmune thyroiditis
Aslı Dogruk unAl1, ozlem TArCın1, HulyA PArılDAr2, ozlem Cıgerlı2,  
HACer eroglu3, nılgun guvener DemırAg1
1Department of Endocrinology and Metabolism, Baskent University Istanbul Hospital, Istanbul, Turkey 
2Department of Family Medicine, Baskent University Istanbul Hospital, Istanbul, Turkey 
3Department of Biochemistry, Baskent University Istanbul Hospital, Istanbul, Turkey
Abstract
Introduction: ıt has been known that vitamin D has some immunomodulatory effects and in au-
toimmune thyroid diseases, vitamin D deficiency was more prevalent. ın this study, our aim was to 
investigate the relationship between thyroid autoantibodies and vitamin D.
Material and methods: Group 1 and 2 consisted of 254 and 27 newly diagnosed Hashimoto’s 
thyroiditis (HT) and Graves’ disease (GD) cases, respectively; age-matched 124 healthy subjects were 
enrolled as controls (group 3). All subjects (n = 405) were evaluated for 25OHD and thyroid autoanti-
body [anti-thyroid peroxidase (anti-TPo) and anti-thyroglobulin (anti-tg)] levels.
Results: Group 2 and group 1 patients had lower 25OHD levels than group 3 subjects 14.9 ±8.6 
ng/ml, 19.4 ±10.1 ng/ml and 22.5 ±15.4 ng/ml, respectively (p < 0.001). Serum 25OHD levels inversely 
correlated with anti-Tg (r = –0.136, p = 0.025), anti-TPO (r = –0.176, p = 0.003) and parathormone 
(PTH) (r = –0.240, p < 0.001). Group 2 patients had higher anti-Tg and anti-TPo levels than group 
1 and 3 (p < 0.001).
Conclusions: ın this study, we found that patients with autoimmune thyroid disease (AıTD) present 
with lower vitamin D levels and gD patients have higher prevalence. since we found an inverse cor-
relation between vitamin D levels and thyroid antibody levels, we may suggest that vitamin D deficiency 
is one of the potential factors in pathogenesis of autoimmune thyroid disorders.
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Introduction
Vitamin D is a lipid soluble vitamin which affects via 
vitamin D receptor (VDR). Vitamin D receptor is an in-
tracellular receptor which belongs to the steroid/thyroid 
nuclear receptor family. This receptor is located in many 
immune cells, such as neutrophils, macrophages, dendritic 
cells, T and B cells. In recent years, apart from its primary 
role in bone and mineral homeostasis, it has been shown 
that vitamin D has potent immunomodulatory effects both 
on the innate and adaptive immune system [1-4]. Vitamin 
D inhibits pro-inflammatory processes by suppressing the 
over-activity of CD4+, Th1, Th2 and Th17 cells and the 
production of their related cytokines by the activation of 
VDR [1, 5]. Epidemiological studies have shown a relation 
between vitamin D deficiency and autoimmune diseases, 
such as rheumatoid arthritis, systemic sclerosis, systemic 
lupus erythematosus and autoimmune thyroiditis [6-8].
Autoimmune thyroid diseases (AITDs), including 
Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and 
postpartum thyroiditis, are the most frequently seen auto-
immune diseases affecting more than 5% of population. In 
recent years, there have been a few studies demonstrating 
an increase in vitamin D deficiency in HT [9, 10].
In this study, our aim was to compare vitamin D lev-
els of newly diagnosed AITDs (GD and HT) and healthy 
controls and investigate the relation between thyroid auto-
antibodies and vitamin D deficiency.
Material and methods
This study was approved by the Baskent University 
Institutional Review Board and Ethics Committee (Project 
no. KA13/176) and supported by the Baskent University 
Research Fund. Informed consent was obtained from all 
patients and healthy controls.
Study population
This study population consisted of newly diagnosed 
AITD adult patients and controls. According to diagno-
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sis, the study population was separated into three different 
groups. Hashimoto’s thyroiditis patients (diagnosed by 
elevated antithyroid peroxidase and antithyroglobulin an-
tibodies (TPOAb, TgAb) and basal thyrotrophic hormone 
(TSH) as well as typical hypoechogenicity of the thyroid 
in high resolution sonography) were included in group 1, 
GD patients [diagnosed by elevated free thyroxine (fT4) and 
suppressed TSH levels and the presence of diffused goiter 
and thyroid receptor antibody (TRAb) positivity] in group 
2 and controls in group 3. Patients with primary liver and 
renal failure, diabetes mellitus, metabolic bone disorders, 
hyperparathyroidism, malignancy, previously known thy-
roid disorders and on oral contraceptive, anticonvulsant, 
anti-osteoporotic therapy and other medications that might 
alter 25(OH)D or 1,25(OH)
2
D metabolism and thyroid func-
tions had been excluded from the study.
Laboratory investigation
For measuring 25(OH)D, TSH, anti-TPO and anti-tg, 
a blood sample was collected by venipuncture at the fast-
ing state, the serum was separated by centrifugation and 
then stored at –70oC for a week until analysed.
Vitamin D: Vitamin D status was evaluated by mea-
surement of serum 25(OH)D levels with a chemilumines-
cent immunoassay method (Architect i1000 system); nor-
mal range was 8.8-46.3 ng/ml (winter); and the intra-assay 
CV ranged from 2.6 to 4.0%. Serum 25(OH)D levels be-
low 20 ng/ml were considered as deficiency.
Parathormone: Serum PTH levels were measured 
with an electrochemiluminescent immunoassay method 
(Architect i2000 system); normal range 15-68 pg/ml; in-
tra-assay CV 3.0-6.5%. Serum calcium (Ca) levels were 
measured with an enzymatic colorimetric assay (C8000 
system); intra-assay and inter-assay CV were 0.5-0.6% 
and 0.3-0.5%, respectively.
Thyrotrophic hormone, anti-Tg, and anti-TPO: 
TSH, anti-TG, and anti-TPO were also measured with 
a chemiluminescent immunoassay method (CMIA) (Ar-
chitect i2000 system, Abbott, USA). The assays have in-
tra-assay precision of 4.3%, 5.8%, and 3.2%, respective-
ly. Positive anti-TPO, and anti-tg were defined as a value 
greater than 5.61 IU/ml and 4.11 IU/ml, respectively.
Statistical analyses
Statistical analyses were performed with the Statistical 
Package for Social Sciences (SPSS for Windows) software 
(version 17.0, SPSS Inc., Chicago, IL, USA). All para-
metric variables were given as mean ± SD or median and 
interquartile range according to distribution of variables. 
Distribution of patients was assessed by using visual (his-
tograms, probability plots) and analytical methods (Kolm-
ogorov-Smirnov/Shapiro-Wilk’s test). The difference 
between categorical variables was analyzed with Chi-
square test and continuous variables were analyzed with 
Mann-Whitney u test. As the vitamin D level was not nor-
mally distributed even after logarithmic transformation, the 
data were compared by the non-parametric Mann-Whitney 
u test. A p-value below 0.05 was considered to be statis-
tically significant.
While investigating the associations between non-nor-
mally distributed and ordinal variables, the correlation co-
efficients and their significance were calculated using the 
Spearman test.
Results
A total of 405 patients were enrolled in our study. The 
mean age was 44.6 ±13.5 years and 89.4% were women in 
the study population. There was no age difference between 
3 groups (p > 0.05). A mean vitamin D level of all partici-
pants was 20.1 ±12 ng/ml. Patients whose serum 25(OH)D 
levels were below 20 ng/ml were considered as vitamin D 
deficient. Sixty five percent (183/281) of the AITDs pa-
tients were vitamin D deficient. When vitamin D deficient 
(n = 183) and sufficient (n = 98) AITDs patients were com-
pared, anti-TG and anti-TPO levels found significantly high 
in the vitamin D deficient group (p = 0.02 and p = 0.003, 
respectively, for anti-tg and anti-TPO) (Table 1).
Group 1, group 2 and group 3 consisted of 254, 27 
and 124 patients, respectively. The prevalence of vitamin 
D insufficiency was 63% and 85.2% in group 1 and 2, re-
spectively. Although the levels of vitamin D were lowest 
in group 2 (Fig. 1), calcium and PTH levels were similar 
between groups. Laboratory results of study population are 
demonstrated in Table 2.
Table 1. Thyroid autoantibody levels according to the vitamin D status
Vitamin D deficient group
(n = 183)
Vitamin D sufficient group
(n = 98)
p value
Vitamin D (ng/ml) 13.4 ±3.6 29.5 ±10 0.001
Anti-TG (IU/ml) 40.4
1.15-1000
19.9
1.12-1000
0.02
Anti-TPO (IU/ml) 170.9
0-1000
36.8
0.06-1000
0.003
Values are expressed as mean ÷ SD or median with interquartile range 
Anti-TG – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody
Central European Journal of Immunology 2014; 39(4)
Vitamin D deficiency is related to thyroid antibodies in autoimmune thyroiditis
495
Multivariate analysis using logistic regression revealed 
that independent determinants of vitamin D levels were age 
and sex (r = 0.17, p = 0.004; r = –0.15, p = 0.01, respectively). 
As expected, there was a negative correlation between vita-
min D and PTH levels (r = –0.24, p < 0.001). When we have 
investigated the association of thyroid autoantibodies, we 
found that there was a significant correlation between these 
autoantibodies and vitamin D and TSH levels (Table 3). Thy-
roid autoantibodies tended to be higher with lower vitamin D 
levels and higher TSH levels. Serum PTH levels, however, 
were not associated with anti-TG and anti-TPO levels.
Discussion
In this case-control study, patients with autoimmune 
thyroid diseases (HT and GD) had lower 25(OH)D levels 
than healthy subjects and vitamin D levels were the lowest 
in GD patients. Since we have known from our previous 
and other Turkish studies that vitamin D deficiency has 
been a prevalent health problem in our country, we adopt-
ed a cutoff level of vitamin D level as 20 ng/ml [21-23]. 
According to this cutoff value, 60.7% of our study popula-
tion had vitamin D deficiency.
It has been known that vitamin D deficiency is not 
correlated with severity of hyperthyroidism [24, 25], and 
antithyroid drugs have immunosuppressive effects. In ad-
dition, thyroid hormones relatively affect renal activity of 
1α-hydroxlase and plasma 1,25(OH)
2
D levels [26, 27]. 
For these reasons, only newly diagnosed AITDs patients 
were included and we measured 25(OH)D level instead of 
1,25(OH)
2
D in our study.
Autoimmune thyroid diseases are relatively common 
organ-specific autoimmune disorders that cause diseases 
ranging in severity from hypothyroidism (HT) to hyperthy-
roidism (GD) [28]. The effects of various environmental 
factors and the intrinsic genetic predisposition of an indi-
vidual may lead to a loss of self-tolerance and contribute 
to the initiation of AITDs. In pathological conditions like 
thyroiditis, infiltrating lymphocytes, cell surface expres-
sion of MHCII, Fas-mediated apoptosis and cytokines re-
Table 2. Characteristics of the study population
group 1 group 2 group 3 p value
TSH (mIU/ml) 2.47
0.16-39.6
0.01
0.001-0.67
1.75
0.32-7.43
< 0.001
Anti-TG (IU/ml) 29.4
1.12-1000
71.1
1.61-1000
1.43
0.46-5.71
< 0.001
Anti-TPO (IU/ml) 117.68
0-1000
281.36
0-1000
0.26
0-4.78
< 0.001
PTH (pg/ml) 46.9
9.14-135.4
48.4
25.1-111.2
43.1
19.9-134.9
0.07
Vitamin D (ng/ml) 17.05
5.4-80
14.9
4-39
19.9
9-122.7
< 0.001
Ca2+ (mg/dl) 9.4
18.4-10.4
9.5
8.4-10.4
9.5
8.4-10.2
0.955
Values are expressed as median with interquartile range. 
TSH – thyroid-stimulating hormone, anti-Tg – thyroglobulin antibody, anti-TPO – anti-thyroid peroxidase antibody, PTH – parathyroid hormone, Ca – calcium
Table 3. Correlation between thyroid autoantibodies and 
vitamin D and TSH levels
Vitamin D TSH
Anti-TG
r
p
–0.13
0.025
0.144
0.018
Anti-TPO
r
p
–0.17
0.003
0.21
0.001
TSH – thyroid-stimulating hormone, anti-Tg – thyroglobulin antibody, anti-
TPO – anti-thyroid peroxidase antibody
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leased from both immune cells and thyrocytes contribute to 
amplification and progression of AITD [29-34]. According 
to this theory, as a result of defective suppressor T cells, 
Th (CD4) cells are able to activate and cooperate with B 
lymphocytes. B lymphocytes activated by T lymphocytes 
produce antibodies that react with thyroid antigens. Stud-
ies on HT and GD patients had reported low vitamin D 
levels [9, 10, 35, 36]. Consistent with the literature, we 
found a lower vitamin D level in patients with autoimmune 
thyroiditis (GD group and HT group) than in controls. In 
addition, this is the first study that found a statistically sig-
nificant negative correlation between serum 25(OH)D and 
anti-TPO, anti-TG levels in both HT and GD patients.
Conclusions
Our findings indicate that patients with AITD present 
with lower vitamin D levels and GD patients have higher 
prevalence. Since we found an inverse correlation between 
vitamin D levels and thyroid antibody levels, we might 
speculate that there might exist a casual relationship. How-
ever, these findings do not clarify whether treatment with 
vitamin D has any beneficial effect on progression or re-
mission of AITD. So, further studies specifically designed 
to evaluate the beneficial effect of vitamin D supplemen-
tation on AITD are needed.
The authors declare no conflict of interest.
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